Viracta Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: San Diego CA United States (2016)

Organization Overview

First Clinical Trial
2018
NCT03397706
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Viracta Therapeutics | Viracta Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

Key: Viracta Therapeutics, Inc. (0) Acquired (2)

cytarabine (cytosar-u) (2 trials)

vosaroxin (12 trials)

Drugs in Phase 2 Trials (5)

Key: Viracta Therapeutics, Inc. (2) Acquired (3)

azacitidine (vidaza) (1 trial)

decitabine (dacogen) (1 trial)

sns-062 (1 trial)

valganciclovir (valcyte) (2 trials)

vrx-3996 (2 trials)

Drugs in Phase 1 Trials (2)

Key: Viracta Therapeutics, Inc. (0) Acquired (2)

bms 387032 (2 trials)

sns-314 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoproliferative Disorders (Phase 2)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 18
  • # of Trial APIs: 9